{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T19:04:01Z","timestamp":1790103841826,"version":"4.0.1"},"reference-count":70,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:00:00Z","timestamp":1790035200000},"content-version":"unspecified","delay-in-days":21,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Gastroenterol"],"accepted":{"date-parts":[[2026,8,14]]},"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:p>The success of inflammatory bowel disease (IBD) clinical trials is strongly influenced by study design and disease-specific operational challenges. Over the past decade, however, IBD clinical trials face slow enrolment, poor retention, accumulating costs and limited representativeness. Trials are further constrained by protocol and operational complexity, financial pressures and regulatory requirements. Carefully selected and optimised trial designs may address the inherent challenges of IBD research and should take into account the patient profiles under investigation, mode of action and speed of onset of effect of the investigational product, among other factors. This narrative review discusses four key study design strategies for IBD clinical trials, including treat-through maintenance, responder re-randomisation, Master Protocol approaches (basket, umbrella and platform trials) and Bayesian methodologies. Treat-through maintenance designs are effective at evaluating sustained efficacy and real-world durability, whereas responder re-randomisation approaches are widely used in drug registration programmes to distinguish induction and maintenance effects for regulator clarity. Master Protocol designs may improve efficiency and reduce placebo exposure, while trials using Bayesian methodologies can strengthen interpretation of efficacy and safety outcomes, particularly in early-phase or complex studies. Key considerations within protocols include the use of co-primary endpoints, selection of secondary\/exploratory endpoints, control group design and integrating digital health technologies, among others. Strategic application of innovative methodologies can improve trial delivery and enhance data robustness and interpretability, thus supporting more efficient development of effective therapies for patients with IBD.<\/jats:p>","DOI":"10.1136\/bmjgast-2026-002489","type":"journal-article","created":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T18:25:22Z","timestamp":1790101522000},"page":"e002489","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Optimising clinical trial design choices in inflammatory bowel disease"],"prefix":"10.1136","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4027-7365","authenticated-orcid":false,"given":"Peter","family":"Bossuyt","sequence":"first","affiliation":[{"name":"Imelda GI Clinical Research Center, Imelda General Hospital, Bonheiden, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"Moscicka","sequence":"additional","affiliation":[{"name":"PSI CRO AG, Zug, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kremena","family":"Stoyanova","sequence":"additional","affiliation":[{"name":"PSI CRO AG, Zug, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Zalud","sequence":"additional","affiliation":[{"name":"PSI CRO AG, Zug, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-3929-6496","authenticated-orcid":false,"given":"Luke M","family":"Shelton","sequence":"additional","affiliation":[{"name":"PSI CRO AG, Zug, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,9,22]]},"reference":[{"key":"2026092211251505000_13.1.e002489.1","first-page":"111","article-title":"Inflammatory bowel disease and anxiety: links, risks, and challenges faced","volume":"8","author":"Bannaga","year":"2015","journal-title":"Clin Exp Gastroenterol"},{"key":"2026092211251505000_13.1.e002489.2","doi-asserted-by":"publisher","DOI":"10.1111\/apt.17370"},{"key":"2026092211251505000_13.1.e002489.3","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1002\/jgh3.12841","article-title":"Chronic steroid use: An overlooked impact on patients with inflammatory bowel disease","volume":"6","author":"Farraj","year":"2022","journal-title":"JGH Open"},{"key":"2026092211251505000_13.1.e002489.4","doi-asserted-by":"crossref","DOI":"10.1186\/s13030-024-00309-5","article-title":"Work-related problems and the psychosocial characteristics of individuals with irritable bowel syndrome: an updated literature review","volume":"18","author":"Sugaya","year":"2024","journal-title":"Biopsychosoc Med"},{"key":"2026092211251505000_13.1.e002489.5","doi-asserted-by":"crossref","first-page":"1676160","DOI":"10.3389\/fimmu.2025.1676160","article-title":"Depression and anxiety in inflammatory bowel disease: mechanisms and emerging therapeutics targeting the microbiota-gut-brain axis","volume":"16","author":"Qian","year":"2025","journal-title":"Front Immunol"},{"key":"2026092211251505000_13.1.e002489.6","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1093\/ecco-jcc\/jjad020","article-title":"Declining Enrolment and Other Challenges in IBD Clinical Trials: Causes and Potential Solutions","volume":"17","author":"Uzzan","year":"2023","journal-title":"J Crohns Colitis"},{"key":"2026092211251505000_13.1.e002489.7","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1093\/ecco-jcc\/jjac134","article-title":"Beyond the White Pill: Advocating for Racial Diversity in IBD Trials","volume":"17","author":"Wong","year":"2023","journal-title":"J Crohns Colitis"},{"key":"2026092211251505000_13.1.e002489.8","unstructured":"Sertkaya A , Birkenback A , Berlind A , et al . Examination of clinical trial costs and barriers for drug development. 2014. Available: https:\/\/aspe.hhs.gov\/reports\/examination-clinical-trial-costs-barriers-drug-development-0 [accessed Aug 2026]"},{"key":"2026092211251505000_13.1.e002489.9","doi-asserted-by":"crossref","DOI":"10.3390\/jcm14072485","article-title":"The Role of Histology Alongside Clinical and Endoscopic Evaluation in the Management of IBD-A Narrative Review","volume":"14","author":"Angyal","year":"2025","journal-title":"J Clin Med"},{"key":"2026092211251505000_13.1.e002489.10","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s00535-020-01678-8","article-title":"Objective evaluation for treat to target in Crohn\u2019s disease","volume":"55","author":"Takenaka","year":"2020","journal-title":"J Gastroenterol"},{"key":"2026092211251505000_13.1.e002489.11","doi-asserted-by":"crossref","unstructured":"Jairath V , Narula N , Ungaro RC , et al . Novel outcomes in inflammatory bowel disease. J Crohns Colitis 2025;19. doi:10.1093\/ecco-jcc\/jjaf040","DOI":"10.1093\/ecco-jcc\/jjaf040"},{"key":"2026092211251505000_13.1.e002489.12","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.cgh.2024.06.036","article-title":"The Future of Clinical Trials in Inflammatory Bowel Disease","volume":"23","author":"Ma","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026092211251505000_13.1.e002489.13","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.12.031"},{"key":"2026092211251505000_13.1.e002489.14","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1016\/j.cgh.2023.09.010","article-title":"Vedolizumab, Adalimumab, and Methotrexate Combination Therapy in Crohn\u2019s Disease (EXPLORER)","volume":"22","author":"Colombel","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026092211251505000_13.1.e002489.15","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1111\/apt.18006","article-title":"Meta-analysis: Persistence of advanced therapies in the treatment of inflammatory bowel disease","volume":"59","author":"Yiu","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"key":"2026092211251505000_13.1.e002489.16","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1111\/apt.70796","article-title":"Comparative Real-World Effectiveness of Anti-TNF, Ustekinumab and Vedolizumab in Crohn\u2019s Disease Over 24\u2009Months: A Pooled Analysis From the Prospective UMBRELLA-IBD Registry in Germany","volume":"64","author":"Bokemeyer","year":"2026","journal-title":"Aliment Pharmacol Ther"},{"key":"2026092211251505000_13.1.e002489.17","unstructured":"National Institutes of Health . A study to evaluate the long-term effect of TEV-48574 in moderate to severe ulcerative colitis or Crohn\u2019s disease (NCT05668013). Available: https:\/\/clinicaltrials.gov\/study\/NCT05668013 [Accessed Aug 2026]."},{"key":"2026092211251505000_13.1.e002489.18","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2021.03.065"},{"key":"2026092211251505000_13.1.e002489.19","doi-asserted-by":"crossref","DOI":"10.1111\/cts.70117","article-title":"Decentralized Clinical Trials in the Era of Real\u2010World Evidence: A Statistical Perspective","volume":"18","author":"Chen","year":"2025","journal-title":"Clinical Translational Sci"},{"key":"2026092211251505000_13.1.e002489.20","doi-asserted-by":"crossref","DOI":"10.1093\/ecco-jcc\/jjaf111","article-title":"Comparison of the FDA and EMA guidance on drug development in ulcerative colitis: an expert panel review","volume":"19","author":"Vieujean","year":"2025","journal-title":"J Crohns Colitis"},{"key":"2026092211251505000_13.1.e002489.21","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00061-2"},{"key":"2026092211251505000_13.1.e002489.22","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00581-5"},{"key":"2026092211251505000_13.1.e002489.23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1900750"},{"key":"2026092211251505000_13.1.e002489.24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606910"},{"key":"2026092211251505000_13.1.e002489.25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2033617"},{"key":"2026092211251505000_13.1.e002489.26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2207940"},{"key":"2026092211251505000_13.1.e002489.27","doi-asserted-by":"crossref","DOI":"10.1093\/crocol\/otad070","article-title":"Mirikizumab Improves Quality of Life in Patients With Moderately-to-Severely Active Ulcerative Colitis: Results From the Phase 3 LUCENT-1 Induction and LUCENT-2 Maintenance Studies","volume":"5","author":"Sands","year":"2023","journal-title":"Crohn\u2019s & Colitis 360"},{"key":"2026092211251505000_13.1.e002489.28","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.therap.2022.12.003","article-title":"Platform trials","volume":"78","author":"Roustit","year":"2023","journal-title":"Therapies"},{"key":"2026092211251505000_13.1.e002489.29","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1053\/j.gastro.2024.04.020","article-title":"Basket, Umbrella, and Platform Trials: The Potential for Master Protocol-Based Trials in Inflammatory Bowel Disease","volume":"167","author":"Honap","year":"2024","journal-title":"Gastroenterology"},{"key":"2026092211251505000_13.1.e002489.30","unstructured":"ISRCTN . A clinical trial to see if a mesenchymal stem cells treatment called ORBCEL-C\u2122 can help to treat primary sclerosing cholangitis, rheumatoid arthritis, lupus nephritis and Crohn\u2019s disease. Available: https:\/\/www.isrctn.com\/ISRCTN80103507 [Accessed Aug 2026]."},{"key":"2026092211251505000_13.1.e002489.31","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/S2468-1253(26)00120-2","article-title":"Efficacy and safety of duvakitug in patients with ulcerative colitis (RELIEVE UCCD): a phase 2b, randomised, placebo-controlled trial","volume":"11","author":"Reinisch","year":"2026","journal-title":"The Lancet Gastroenterology & Hepatology"},{"key":"2026092211251505000_13.1.e002489.32","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/S2468-1253(26)00119-6","article-title":"Efficacy and safety of duvakitug in patients with Crohn\u2019s disease (RELIEVE UCCD): a phase 2b, randomised, placebo-controlled trial","volume":"11","author":"Jairath","year":"2026","journal-title":"The Lancet Gastroenterology & Hepatology"},{"key":"2026092211251505000_13.1.e002489.33","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.1016\/j.cgh.2022.12.029","article-title":"Oral Ritlecitinib and Brepocitinib for Moderate-to-Severe Ulcerative Colitis: Results From a Randomized, Phase 2b Study","volume":"21","author":"Sandborn","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026092211251505000_13.1.e002489.34","doi-asserted-by":"crossref","first-page":"103820","DOI":"10.1016\/j.eclinm.2026.103820","article-title":"Once-daily oral ritlecitinib or brepocitinib versus placebo in patients with moderate-to-severely active Crohn\u2019s disease (PIZZICATO): an international, randomised, phase 2a trial","volume":"93","author":"Vermeire","year":"2026","journal-title":"eClinicalMedicine"},{"key":"2026092211251505000_13.1.e002489.35","first-page":"365","article-title":"Platform trials for rare cancers\u2014A complex innovation to accelerate knowledge","volume":"11","author":"Hau","year":"2024","journal-title":"Neurooncol Pract"},{"key":"2026092211251505000_13.1.e002489.36","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2020.04.025"},{"key":"2026092211251505000_13.1.e002489.37","unstructured":"National Institutes of Health . A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease (MACARONI-23) (NCT05923073). Available: https:\/\/clinicaltrials.gov\/study\/NCT05923073 [Accessed Aug 2026]."},{"key":"2026092211251505000_13.1.e002489.38","unstructured":"National Institutes of Health . A study of long-acting antibodies alone and in combinations for moderate to severe ulcerative colitis (SKYLINE-UC) (NCT07012395). Available: https:\/\/clinicaltrials.gov\/study\/NCT07012395 [Accessed Aug 2026]."},{"key":"2026092211251505000_13.1.e002489.39","unstructured":"National Institutes of Health . A phase 2 study to evaluate therapies for inflammatory bowel disease (ASCEND-IBD) (NCT07113522). Available: https:\/\/clinicaltrials.gov\/study\/NCT07113522 [Accessed Aug 2026]."},{"key":"2026092211251505000_13.1.e002489.40","unstructured":"European Medicines Agency. Concept paper on platform trials 2022, Available: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/concept-paper-platform-trials_en.pdf [Accessed Aug 2026]."},{"key":"2026092211251505000_13.1.e002489.41","unstructured":"U.S. Food and Drug Administration . Use of Bayesian methodology in clinical trials of drug and biological products. 2026. Available: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/use-bayesian-methodology-clinical-trials-drug-and-biological-products [Accessed Aug 2026]."},{"key":"2026092211251505000_13.1.e002489.42","doi-asserted-by":"crossref","unstructured":"Noor NM , Zheng H , Cao Z , et al . Bayesian prior elicitation on the efficacy of medical therapies in perianal fistulizing Crohn\u2019s disease. Journal of Crohn\u2019s and Colitis 2026;20. doi:10.1093\/ecco-jcc\/jjag061","DOI":"10.1093\/ecco-jcc\/jjag061"},{"key":"2026092211251505000_13.1.e002489.43","doi-asserted-by":"crossref","unstructured":"Siddique J , Aghabazaz Z . Prior Ground: Selection of Prior Distributions When Analyzing Clinical Trial Data Using Bayesian Methods. NEJM Evidence 2023;2. doi:10.1056\/EVIDe2300250","DOI":"10.1056\/EVIDe2300250"},{"key":"2026092211251505000_13.1.e002489.44","doi-asserted-by":"crossref","first-page":"5267","DOI":"10.3390\/jcm14155267","article-title":"Adaptive Bayesian Clinical Trials: The Past, Present, and Future of Clinical Research","volume":"14","author":"Berry","year":"2025","journal-title":"JCM"},{"key":"2026092211251505000_13.1.e002489.45","unstructured":"National Institutes of Health . A study of vedolizumab intravenous (iv) and adalimumab or vedolizumab and ustekinumab in adults with Crohn\u2019s disease (NCT06045754). Available: https:\/\/clinicaltrials.gov\/study\/NCT06045754 [Accessed Aug 2026]."},{"key":"2026092211251505000_13.1.e002489.46","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2011-301668"},{"key":"2026092211251505000_13.1.e002489.47","doi-asserted-by":"crossref","first-page":"902","DOI":"10.14309\/ajg.0000000000001800","article-title":"Personalized Research on Diet in Ulcerative Colitis and Crohn\u2019s Disease: A Series of N-of-1 Diet Trials","volume":"117","author":"Kaplan","year":"2022","journal-title":"Am J Gastroenterol"},{"key":"2026092211251505000_13.1.e002489.48","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.jclinepi.2020.03.021","article-title":"Bayesian analysis from phase III trials was underused and poorly reported: a systematic review","volume":"123","author":"Ferreira","year":"2020","journal-title":"J Clin Epidemiol"},{"key":"2026092211251505000_13.1.e002489.49","doi-asserted-by":"publisher","DOI":"10.1016\/j.bja.2020.04.093"},{"key":"2026092211251505000_13.1.e002489.50","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.1093\/ibd\/izaf148","article-title":"Bayesian Statistics: A Narrative Review on Application in Inflammatory Bowel Diseases","volume":"31","author":"Camara","year":"2025","journal-title":"Inflamm Bowel Dis"},{"key":"2026092211251505000_13.1.e002489.51","doi-asserted-by":"publisher","DOI":"10.1007\/s43441-021-00357-x"},{"key":"2026092211251505000_13.1.e002489.52","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(89)90905-0"},{"key":"2026092211251505000_13.1.e002489.53","doi-asserted-by":"publisher","DOI":"10.3109\/07853890109002087"},{"key":"2026092211251505000_13.1.e002489.54","doi-asserted-by":"publisher","DOI":"10.1097\/00005650-199206000-00002"},{"key":"2026092211251505000_13.1.e002489.55","doi-asserted-by":"publisher","DOI":"10.1016\/j.trsl.2012.01.001"},{"key":"2026092211251505000_13.1.e002489.56","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.641436","article-title":"The Placebo and Nocebo Responses in Clinical Trials in Inflammatory Bowel Diseases","volume":"12","author":"Enck","year":"2021","journal-title":"Front Pharmacol"},{"key":"2026092211251505000_13.1.e002489.57","article-title":"Placebo response and remission rates in randomised trials of induction and maintenance therapy for ulcerative colitis","volume":"9","author":"Jairath","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"2026092211251505000_13.1.e002489.58","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/S2468-1253(24)00233-4","article-title":"Harms with placebo in trials of biological therapies and small molecules as maintenance therapy in inflammatory bowel disease: a systematic review and meta-analysis","volume":"9","author":"Gros","year":"2024","journal-title":"The Lancet Gastroenterology & Hepatology"},{"key":"2026092211251505000_13.1.e002489.59","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/S2468-1253(24)00264-4","article-title":"Harms with placebo in trials of biological therapies and small molecules as induction therapy in inflammatory bowel disease: a systematic review and meta-analysis","volume":"9","author":"Din","year":"2024","journal-title":"The Lancet Gastroenterology & Hepatology"},{"key":"2026092211251505000_13.1.e002489.60","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1053\/j.gastro.2025.05.015","article-title":"An International Consensus on Appropriate Management of Corticosteroids in Clinical Trials in Inflammatory Bowel Disease","volume":"169","author":"Han\u017eel","year":"2025","journal-title":"Gastroenterology"},{"key":"2026092211251505000_13.1.e002489.61","unstructured":"European Medicines Agency . ICH e9 (r1) addendum on estimands and sensitivity analysis in clinical trials to the guideline on statistical principles for clinical trials. 2020. Available: https:\/\/www.ema.europa.eu\/en\/ich-e9-statistical-principles-clinical-trials-scientific-guideline [accessed Aug 2026]"},{"key":"2026092211251505000_13.1.e002489.62","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1093\/ecco-jcc\/jjae026","article-title":"Pragmatic Trial Design to Compare Real-world Effectiveness of Different Treatments for Inflammatory Bowel Diseases: The PRACTICE-IBD European Consensus","volume":"18","author":"Fantini","year":"2024","journal-title":"J Crohns Colitis"},{"key":"2026092211251505000_13.1.e002489.63","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1093\/ibd\/izae233","article-title":"Screen Failures and Causes in Inflammatory Bowel Disease Randomized Controlled Trials: A Study of 16 913 Screened Patients","volume":"31","author":"Uzzan","year":"2025","journal-title":"Inflamm Bowel Dis"},{"key":"2026092211251505000_13.1.e002489.64","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.cgh.2023.09.011","article-title":"Washout Periods in Inflammatory Bowel Disease Trials: A Systematic Literature Review and Proposed Solutions","volume":"22","author":"Wils","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026092211251505000_13.1.e002489.65","doi-asserted-by":"crossref","first-page":"106141","DOI":"10.1016\/j.ijmedinf.2025.106141","article-title":"Artificial intelligence in clinical trials: A comprehensive review of opportunities, challenges, and future directions","volume":"206","author":"Olawade","year":"2026","journal-title":"Int J Med Inform"},{"key":"2026092211251505000_13.1.e002489.66","doi-asserted-by":"crossref","DOI":"10.1093\/crocol\/otae019","article-title":"Toward Patient Centricity: Why Do Patients With Inflammatory Bowel Disease Participate in Pharmaceutical Clinical Trials? A Mixed-Methods Exploration of Study Participants","volume":"6","author":"Solitano","year":"2024","journal-title":"Crohn\u2019s & Colitis 360"},{"key":"2026092211251505000_13.1.e002489.67","doi-asserted-by":"crossref","DOI":"10.2196\/14165","article-title":"The Telemedicine for Patients With Inflammatory Bowel Disease (TELE-IBD) Clinical Trial: Qualitative Assessment of Participants\u2019 Perceptions","volume":"21","author":"Quinn","year":"2019","journal-title":"J Med Internet Res"},{"key":"2026092211251505000_13.1.e002489.68","unstructured":"Stern AD , Trusheim M . Transformation of the clinical trial enterprise: lessons learned from the covid-19 pandemic. Washington (DC) Office of the Assistant Secretary for Planning and Evaluation (ASPE); 2024."},{"key":"2026092211251505000_13.1.e002489.69","unstructured":"McKenzie H . JPM26: beam, cabaletta, more zero in on regulatory alignment after tumultuous year. Available: https:\/\/www.biospace.com\/fda\/jpm26-beam-cabaletta-more-zero-in-on-regulatory-alignment-after-tumultuous-year [Accessed Aug 2026]."},{"key":"2026092211251505000_13.1.e002489.70","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1093\/ibd\/izad314","article-title":"The Clinical Interpretation of Noninferiority Trials","volume":"30","author":"Roshanov","year":"2024","journal-title":"Inflamm Bowel Dis"}],"container-title":["BMJ Open Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjgast-2026-002489","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T18:25:31Z","timestamp":1790101531000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopengastro.bmj.com\/lookup\/doi\/10.1136\/bmjgast-2026-002489"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":70,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,9,22]]},"published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10.1136\/bmjgast-2026-002489"],"URL":"https:\/\/doi.org\/10.1136\/bmjgast-2026-002489","relation":{},"ISSN":["2054-4774"],"issn-type":[{"value":"2054-4774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9]]}}}